Filtered By:
Drug: Lipitor

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 875 results found since Jan 2013.

Clinical Reasoning: A 66-year-old man with recurrent multi-territory infarcts
A 66-year-old man was referred to our center for evaluation of recurrent infarcts in multiple vascular territories over the preceding 6 months (figure 1). The patient first presented with a 3-month, stuttering course of transient neurologic deficits, including right arm and leg hemiparesis, expressive aphasia, and right homonymous hemianopia. He was initially evaluated at a community Stroke Prevention Clinic. His medical history was significant for several classic vascular risk factors: coronary artery disease requiring a coronary artery bypass graft, dyslipidemia for which he was taking atorvastatin 20 mg daily, and obstr...
Source: Neurology - June 8, 2015 Category: Neurology Authors: Kouzmitcheva, E., Steriade, C., Prica, A., Hazrati, L.-N., Mandell, D. M. Tags: All Cerebrovascular disease/Stroke, All Education RESIDENT AND FELLOW SECTION Source Type: research

Effect of atorvastatin co‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
Source: International Journal of Stroke - November 18, 2015 Category: Neurology Authors: Atsushi Mizuma, Kazuyuki Iijima, Saori Kohara, Mie Shimizu, Ryoko Imazeki, Tsuyoshi Uesugi, Yoichi Ohnuki, Shunya Takizawa Tags: Letter to the editor Source Type: research

Effect of atorvastatin co ‐treatment on inhibition of platelet activation by clopidogrel in patients with ischemic stroke
Source: International Journal of Stroke - November 17, 2015 Category: Neurology Authors: Atsushi Mizuma, Kazuyuki Iijima, Saori Kohara, Mie Shimizu, Ryoko Imazeki, Tsuyoshi Uesugi, Yoichi Ohnuki, Shunya Takizawa Tags: Letter to the editor Source Type: research

Polymorphisms of the apolipoprotein E gene affect response to atorvastatin therapy in acute ischemic stroke
CONCLUSION: APOE gene polymorphisms affect the biological functions of atorvastatin. Compared to the ε3 or ε4 allele, the ε2 allele exerted a greater lipid-lowering effect on LDL-C levels, enhanced the ability of atorvastatin to stabilize carotid artery plaques, and slowed carotid artery plaque progression.PMID:36426228 | PMC:PMC9678920 | DOI:10.3389/fcvm.2022.1024014
Source: Atherosclerosis - November 25, 2022 Category: Cardiology Authors: QianQian Bi XiaoYu Zhou YanQin Lu Wang Fu YongPeng Wang Feng Wang Jue Wang Source Type: research

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Cerebrovascular Disease and Statins
Front Cardiovasc Med. 2021 Dec 2;8:778740. doi: 10.3389/fcvm.2021.778740. eCollection 2021.ABSTRACTElevated low-density lipoprotein-cholesterol (LDL-C) is a causal factor for the development of atherosclerotic cardiovascular disease (ASCVD); accordingly, LDL-C lowering is associated with a decreased risk of progression of atherosclerotic plaques and development of complications. Currently, statins play a central role in any ASCVD management and prevention strategies, in relation to their lipid-lowering action and potentially to pleiotropic effects. After coronary artery disease, stroke is the most frequent cause of ASCVD m...
Source: Atherosclerosis - December 20, 2021 Category: Cardiology Authors: Luis M Beltr án Romero Antonio J Vallejo-Vaz Ovidio Mu ñiz Grijalvo Source Type: research

Statins are 'safe, effective and should be used more widely'
Conclusion This study reviews evidence from randomised controlled trials (RCTs) and observational studies to better evaluate the effects and safety of statin therapy. It provides valuable data on the size of the benefits compared with the risks, informing a topic that has had much media coverage in recent times. The researchers highlight that the benefits of statin therapy for people at risk of cardiovascular disease events far outweigh any possible side effects. But it is still for a doctor and their patient to come to a conclusion about what the best treatment for them may be. If you have been prescribed a statin, it...
Source: NHS News Feed - September 9, 2016 Category: Consumer Health News Tags: QA articles Medication Heart/lungs Source Type: news

A meta-analysis of pharmacological neuroprotection in noncardiac surgery: focus on statins, lidocaine, ketamine, and magnesium sulfate.
CONCLUSIONS: The available clinical data are still scarce. Our analyses indicate no protective effects by statins against perioperative stroke but some favorable trends toward delayed stroke. Further randomized trials are needed to unequivocally assess the neuroprotective potential of current pharmacological agents in non-cardiac surgery. PMID: 29630129 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 10, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

New drug shows promise in preventing heart attacks
Conclusion This is a high-quality, well-conducted randomised controlled trial conducted in a very large number of people across multiple countries. To date, it's remained uncertain whether evolocumab reduces the risk of cardiovascular events. This study provides good evidence that the drug reduces the risk of major cardiovascular events in people with high LDL cholesterol levels, and with a high risk of having a cardiovascular event, who are already taking statins. The follow-up is limited to around two years, during which roughly 1 in 10 people experienced a cardiovascular event. The reduction in risk was shown to inc...
Source: NHS News Feed - March 20, 2017 Category: Consumer Health News Tags: Medication Heart/lungs Source Type: news